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INTRODUCTION
Bone tissue engineering has been an increasing field of research during the last years. The ideal approach for a regenerative application would consist in 
the use of cells from the patient, scaffolding materials and differentiation growth factors. Bone morphogenetic protein-2 (BMP-2) is one such growth factors 
with a strong ability to induce new bone and cartilage formation and has been used as a powerful osteoinductive component of several late-stage tissue 
engineering products for bone grafting. In this work, we aimed at obtaining high yields of human recombinant BMP-2 in a stable, pure and biologically active 
form by use of a new bacteria expression system that circumvents the disadvantages of conventional recombinant protein preparation methods and to 
perform a study of the stability conditions and the functionality of these peptides in vitro in human mesenchymal stem cells and C2C12 murine cell line.  
CONCLUSIONS
Ø The novel approach described herein shows to be a promising way for 
obtaining large amounts of partially purified rhBMP-2 which shows evidence 
of bioactivity, capable of inducing some markers of specific osteogenic 
(bone) differentiation and showing no relevant cytotoxicity.
MATERIALS & METHODS
Fig. 1. The sequence coding for mature rhBMP-2 was cloned in a pET-25b 
vector and expressed in BL21DE3 E. coli strain. This vector permitted 
expression of recombinant protein into periplasm where ambient is 
permissive to the formation of cysteine bridges of folded protein. 
rhBMP-2 was then purified by high affinity chromatography and 
size exclusion chromatography and tested in C2C12 cell line. This 
is a well-studied and stable model for testing the in vitro biological 
activity of recombinant BMPs.
RESULTS & DISCUSSION
Purification by size exclusion chromatography
Biological activity assays
Fig. 4. Western-blot, non-reduced 
conditions permitted visualization 
of monomer, dimer and polymer
fractions. An antibody against the 
6x histidine tag was used. 
rhBMP-2 was stabilized at pH 10 in 
PBS 0.5M L-arginine
Fig. 5. Size exclusion chromatography permitted partial separation of monomer, 
dimer and polymer fractions, as analysed by Western-blot.
Fig. 3. Silver stained reduced SDS-PAGE 
reveals purification growth factor to up 95%
Purification of rhBMP-2 by high affinity chromatography
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Two variants of rhBMP-2 were 
produced: variant I containing two 
adjacent sites for protease cleavage 
in order to eliminate plasmid tags and 
variant II containing the protein with 
no additional cleavage sites.
Fig. 7. Addition of 5-500ng/ml rhBMP-2 to 
human adipose mesenchymal stem cells 
resulted in changes of morphology
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Fig. 2. Expression of recombinant bacteria was 
performed in a fermentor allowing large yields 
of rhBMP-2, around 110mg/L.For future bone biomedical applications!
Fig. 6. MTS assay revealed no 
cytotoxicity of purified rhBMP-2
ALP
Runx2/Cbfa1
Smad1
Smad5
Osteocalcin
Osterix
Polymerase II
Fig. 8. RT-PCR shows increase of specific 
markers of osteogenic differentiation (ALP, 
Smad-5, runx2, osteocalcin) when C2C12 
cells were stimulated with 500ng/ml of our 
rhBMP-2  stabilized at pH 10.
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